TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05048251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cTBS
Description: continuous theta burst stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS
Description: intermittent theta burst stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham
Description: sham stimulation
Study: NCT05704920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IA
Description: The multidisciplinary team meeting discussion is informed of the AI-based analysis of their chest computed tomography

Intervention type: OTHER
Group type: OTHER
Intervention: Not IA
Description: The multidisciplinary team meeting discussion is not informed of the AI-based analysis of their chest computed tomography
Study: NCT05882617

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: implants supported overdentures
Description: implant supported and retained with different number of implants retained by ball attachments

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: implants supported overdentures
Description: implant supported and retained with different number of implants retained by ball attachments

Intervention type: OTHER
Group type: OTHER
Intervention: implants supported overdentures
Description: implant supported and retained with different number of implants retained by ball attachments
Study: NCT06270667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Participants receive twice weekly supervised aerobic treadmill-based exercise sessions for five months. Session duration varies from 20 to 60 minutes, including warm-up, with exercise intensity ranging from 60 to 95% of peak heart rate. Maximal exercise capacity (VO2peak and peak heart rate) will be determined by the CPET performed by certified exercise physiologists at baseline.The exercise prescription will be sequenced so that the exercise intensity and -duration of each exercise varies within each week, leading to an accumulative increase in weekly exercise volume throughout the intervention. This intervention is also given to the Active Comparator group (i.e. non-cancer reference group)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Participants receive twice weekly supervised aerobic treadmill-based exercise sessions for five months. Session duration varies from 20 to 60 minutes, including warm-up, with exercise intensity ranging from 60 to 95% of peak heart rate. Maximal exercise capacity (VO2peak and peak heart rate) will be determined by the CPET performed by certified exercise physiologists at baseline.The exercise prescription will be sequenced so that the exercise intensity and -duration of each exercise varies within each week, leading to an accumulative increase in weekly exercise volume throughout the intervention. This intervention is also given to the Active Comparator group (i.e. non-cancer reference group)
Study: NCT04888988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participate in the Exercise for Cancer Patients (EXCAP) intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tactile Sensitivity Test
Description: Participants undergo tactile sensitivity test

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tactile Sensitivity Test
Description: Participants undergo tactile sensitivity test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Participants complete questionnaires

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Participants complete questionnaires

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain Magnetic Resonance Imaging
Description: Participants may have options to complete brain MRI scans

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brain Magnetic Resonance Imaging
Description: Participants may have options to complete brain MRI scans
Study: NCT05219253

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HZ/su
Description: Two doses of the HZ/su vaccine administered intramuscularly, one each at Day 1 and Month 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two doses of Placebo (lyophilised sucrose reconstituted with saline \[NaCl\] solution) administered intramuscularly, one each at Day 1 and Month 2.
Study: NCT05076942

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with cisplatin
Description: Inguinofemoral radiotherapy combined with weekly cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Inguinofemoral radiotherapy combined with weekly cisplatin
Study: NCT04572945

Intervention type: DIAGNOSTIC_TEST
Intervention: kidney function test
Description: laboratory and imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: kidney function test
Description: laboratory and imaging
Study: NCT05286489

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Qigong exercise
Description: The qigong style they learned is known as 18 Forms Tai Chi Internal Qigong. It is a kind of physical and mental exercise (internal qigong) that focuses on relaxation, deep breathing, and slow and coordinated movements and uses the mind to guide these movements. There are a total of 18 upper and lower body movements, and all of the techniques are performed while either standing or semi squatting. qigong practice session was initiated immediately and continued for about 6 minutes. Each participant in the qigong group performed 18 Forms Tai Chi Internal Qigong once and was assessed immediately afterward in sitting (to measure the vascular outcomes) and lying (to measure the upper limb circumference) positions. The control participants were given no specific exercise instruction after the baseline assessment. Instead, they were asked to rest (sit quietly in the laboratory) for 6 minutes and then participated in the postassessment directly

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Qigong exercise
Description: The qigong style they learned is known as 18 Forms Tai Chi Internal Qigong. It is a kind of physical and mental exercise (internal qigong) that focuses on relaxation, deep breathing, and slow and coordinated movements and uses the mind to guide these movements. There are a total of 18 upper and lower body movements, and all of the techniques are performed while either standing or semi squatting. qigong practice session was initiated immediately and continued for about 6 minutes. Each participant in the qigong group performed 18 Forms Tai Chi Internal Qigong once and was assessed immediately afterward in sitting (to measure the vascular outcomes) and lying (to measure the upper limb circumference) positions. The control participants were given no specific exercise instruction after the baseline assessment. Instead, they were asked to rest (sit quietly in the laboratory) for 6 minutes and then participated in the postassessment directly
Study: NCT04484675

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone inhalation
Description: After induction of anesthesia and stable hemodynamics inhaled milrinone( 1 mg/ml) is initiated and intravenous placebo ( normal saline )infusion are administered
Study: NCT04318379

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HCVax
Description: HCVax is a lentiviral vector encoding several HCV antigens

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HCVax
Description: HCVax is a lentiviral vector encoding several HCV antigens
Study: NCT05632848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide combined with Zimberelimab
Description: Chidamide: 30mg each time, orally, biw; Zimberelimab, 240mg, IV, every 3 weeks.
Study: NCT04655963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
Study: NCT05862948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENDO-Aid by Olympus
Description: Colonoscopy assisted by ENDO-AID device
Study: NCT02571608

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: The study intervention involves Type II Diabetes Mellitus patient self-administered metformin vs. placebo according to regular dosing schedule and randomization. Both placebo and active drug will be over-encapsulated by pharmacy so that they will be indistinguishable to the personnel involved in the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study intervention involves Type II Diabetes Mellitus patient self-administered metformin vs. placebo according to regular dosing schedule and randomization. Both placebo and active drug will be over-encapsulated by pharmacy so that they will be indistinguishable to the personnel involved in the study.
Study: NCT06402903

Intervention type: OTHER
Intervention: Observation
Description: The clinical, post-surgical and anthropometric variables of the patients, as well as the time spent in the Intensive Care Unit and on the hospital ward (in days) were collected in the Clinical Histories.~The collection of data from the Clinical Histories will be carried out by the principal investigator, an employee of the Hospital Universitario Central de Asturias, in accordance with current data protection regulations, scrupulously complying with the anonymous collection of clinical data, and without collecting any data that could allow the identification of the patients whose data were collected.~The data from the Clinical Histories will be exported to an Excel file which will subsequently be anonymised. Access to the Excel file will require a password access that will be managed from a computer of the University of Oviedo (Department of Surgery and Medical-Surgical Specialties).
Study: NCT05608330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PETRUSHKA tool
Description: In the experimental arm, the PETRUSHKA tool will automatically select the antidepressants that have the best profile in terms of efficacy and acceptability for each individual participant (based on their baseline demographic and clinical characteristics) and then ask the participant to provide their preferences about common (and non-serious) adverse events. Based on patient's preferences and their individual characteristics, the PETRUSHKA tool will then identify the three best antidepressants for the participant. The clinician and the participant will be presented with an overall recommendation (in the format of a pictogram) showing how strongly each antidepressant is recommended for that individual patient. Via a shared decision-making process, the participant and the clinician will then agree on which antidepressant to choose from the shortlist.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Any antidepressant prescribed by clinician based upon their clinical judgement.
Study: NCT04919746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systemic acupuncture
Description: Systemic acupuncture will be performed on the lower limb, bilaterally, at points E36 (Zusanli) and BP6 (Sanyinjiao). Point location specificity will be determined using the anatomical and directional F-cun reference method. Stimulation of pre-defined points will be performed using needles with a threadlike, sterile, disposable character and size 0.25 x 30.0 mm, within a period of 20 minutes. The insertion of the needle will be at a depth of 0.5 inches, aiming to obtain the De Qi, sensation of energy at the point and in the corresponding meridian, referring to the effectiveness of systemic acupuncture.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systemic acupuncture
Description: Systemic acupuncture will be performed on the lower limb, bilaterally, at points E36 (Zusanli) and BP6 (Sanyinjiao). Point location specificity will be determined using the anatomical and directional F-cun reference method. Stimulation of pre-defined points will be performed using needles with a threadlike, sterile, disposable character and size 0.25 x 30.0 mm, within a period of 20 minutes. The insertion of the needle will be at a depth of 0.5 inches, aiming to obtain the De Qi, sensation of energy at the point and in the corresponding meridian, referring to the effectiveness of systemic acupuncture.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systemic acupuncture
Description: Systemic acupuncture will be performed on the lower limb, bilaterally, at points E36 (Zusanli) and BP6 (Sanyinjiao). Point location specificity will be determined using the anatomical and directional F-cun reference method. Stimulation of pre-defined points will be performed using needles with a threadlike, sterile, disposable character and size 0.25 x 30.0 mm, within a period of 20 minutes. The insertion of the needle will be at a depth of 0.5 inches, aiming to obtain the De Qi, sensation of energy at the point and in the corresponding meridian, referring to the effectiveness of systemic acupuncture.
Study: NCT05716594

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Plant enteral-extended anti-reflux stents
Description: Plant enteral-extended anti-reflux stents in EUS-guided drainage of pancreatic pseudocysts

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Plant traditional stents
Description: Plant traditional stents in EUS-guided drainage of pancreatic pseudocysts
Study: NCT05138237

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopy or surgery
Description: we choose the proper intervention surgery or endoscopy for management of the indeterminate common bile duct stricture according to its nature benign or malignant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopy or surgery
Description: we choose the proper intervention surgery or endoscopy for management of the indeterminate common bile duct stricture according to its nature benign or malignant
Study: NCT06068179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil, Oral, 250 Mg
Description: Mycophenolate Mofetil, Oral, 500Mg twice daily for 12 months, combined with methimazole standard therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methimazole, oral, 10mg
Description: Methimazole 15-30mg daily initially then titrate to maintenance dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methimazole, oral, 10mg
Description: Methimazole 15-30mg daily initially then titrate to maintenance dose.
Study: NCT05096494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-103
Description: SP-103 topical system is worn daily for 12 hours per day for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo topical system is worn daily for 12 hours per day, for 28 days
Study: NCT05479305

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Valiant Captivia Stent Graft
Description: Aortic arch/Descending aorta Repair
Study: NCT06131229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured emotional education program (PEE)
Description: The principal investigator, together with the class-tutor of the experimental groups, conducts the 20 activities of which the program is composed during the hour dedicated to tutorial action. The sessions are held at Lauro School on Monday mornings in the respective classrooms, with the possibility of using the courtyard and other multipurpose rooms if the activities so require. Each session lasts one hour and is held throughout the school year 23-24.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Incidental tutorial action based on the school's regular curriculum (PCO)
Description: One hour tutorial action per week according to the regular school curriculum. This curriculum contemplates the incidental approach to the problems that arise in daily life and the work with the KIVA program.
Study: NCT05991557

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peroneus longus autograft
Description: Peroneus longus tendon graft will be harvested with a longitudinal skin incision at 2 to 3 cm (2 finger-breadths) above and 1 cm (1 finger-breadth) behind the lateral malleolus, followed by superficial fascia incision in line with skin incision followed by incision of the tendon sheath proximal to the retinaculum. The peroneus longus and peroneus brevis tendons will be then identified. The tendon division location marked at 2 to 3 cm above the level of the lateral malleolus.The peroneus longus tendon will be exposed on its posterolateral surface through the incision after carefully incising the fascia
Study: NCT05448599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6MW3211 injection with Intravenous Infusion
Description: phaseI: 6MW3211 will be administered in 30mg/kg and 45mg/kg intravenously once every 2 weeks; phaseII: 6MW3211 will be administered in 45mg/kg intravenously in both 2 cohorts.AZA will be administered in 75mg/m2 by subcoutaneous injection in cohort 1 as well as cohort 2 from Day1-Day7 every 28-day cycle. VEN will be administered orally with dose escalation to 400mg daily every cycle.
Study: NCT04484675

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone infusion
Description: After induction of anesthesia and stable hemodynamics inhaled placebo( normal saline) is initiated and intravenous ( 1 mg/ml) (0.5 μg/kg/min)infusion are administered
Study: NCT05821452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mgQ3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175mg/m2，D1，Q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175mg/m2，D1，Q3w
Study: NCT05145582

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Self-Guided PSP Wellbeing Course
Description: An unguided version of a transdiagnostic ICBT program that has shown promising initial outcomes in prior research (https://doi.org/10.2196/27610).
Study: NCT05821452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m2，D1，Q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m2，D1，Q3w

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 41.4Gy, 1.8Gy each time, 5 times a week
Study: NCT06057805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blinded Dexcom G7 CGM
Description: CGM that records blood glucose but not visible to patient or provider in real time
Study: NCT03095404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Lidocaine
Description: 60 cc syringe with 2 vials of 1% lidocaine (40cc's) low dose solution using adjusted body weight formula

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Lidocaine
Description: 60 cc syringe with 2 vials of 2% lidocaine (40 cc's) high dose solution using adjusted body weight formula
Study: NCT05145582

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Self-Guided PSP Wellbeing Course
Description: An unguided version of a transdiagnostic ICBT program that has shown promising initial outcomes in prior research (https://doi.org/10.2196/27610).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Discussion Forum
Description: An online discussion forum designed to provide an opportunity for participants to support one another in their use of the ICBT program.
Study: NCT05435716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-wave™ peripheral seismic waveguide system
Description: In the experimental group, if the target lesions did not show flow-limiting dissection or severe elastic retraction, drug-coated balloon was subsequently performed after lumen preparation by peripheral seismic catheterization system (IVL). If there is limited flow dissection or severe elastic retraction, stent therapy is followed.

Intervention type: DEVICE
Group type: OTHER
Intervention: Peripheral vascular balloon dilatation catheter (PTA)
Description: Subjects in the control group received balloon dilatation catheter in peripheral blood for lumen preparation, and if the target lesions did not show flow-limiting interlayer or severe elastic retraction, drug-coated balloon therapy was subsequently performed. If there is limited flow dissection or severe elastic retraction, stent therapy is followed.
Study: NCT06123611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adopting Comprehensive Training for FireArm Safety in Trauma centers
Description: Firearm access screening, brief firearm safe storage intervention, and referral to community and preventive health resources
Study: NCT04467814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Better Together
Description: Patient and caregiver dyads from both groups will receive usual care during hospitalization and following discharge. This will include a handout on strategies for safely remaining active.~Caregiver participants in the intervention group will receive up to six telephone or video calls with the research assistant or Clinical Resource Therapist. Sessions will review the knowledge translation (KT) product with family members (\~15 minutes), art goals, brainstorm strategies, and discuss setbacks. The calls with the caregiver may occur 1 to 2 times in the hospital, within one week of going home, and then in Months 2 and 3.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patient and caregiver dyads from both groups will receive usual care during hospitalization and following discharge. This will include a handout on strategies for safely remaining active.
Study: NCT04812431

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neural precursor cells derived from human embryonic stem cell line
Description: When the Dose Limiting Toxicity (DLT) is not presented in the first three subjects administered with PSA-NCAM(+) NPC, two additional patients are added to the clinical study.
Study: NCT05498532

Intervention type: DIAGNOSTIC_TEST
Intervention: Functional MRI
Description: Anatomical MRI : T2 fiesta, SSFE, HASTE ; 3D T2 ; T1 FAT SAT ; LAVA Functional MRI : T1 FAT SAT with gadolinium
Study: NCT05580354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG combined with Tislelizumab
Description: Patients will receive 17 cycles of Tislelizumab (200mg per cycle) in combination with BCG (6-week induction course of 120mg followed by maintenance with 3 weekly infusions of 120mg at months 3,6,12).
Study: NCT05617118

Intervention type: DRUG
Intervention: Baclofen 10mg
Description: Baclofen is a medication, a central myorelaxant, a GABAb stimulator.

Intervention type: DRUG
Intervention: Botulinum toxin type A
Description: Botulinum toxin, often shortened to BoNT, is a neurotoxic protein produced by the bacterium Clostridium botulinum and related species.